遗传检测在单基因肾结石病中不断演变的作用:聚焦原发性高草酸尿症
本文为叙述性综述,讨论疑似单基因肾结石病进行遗传检测的获益与实践,以及多学科团队的关键作用;作者结合自身经验提出,增加遗传检测可促进原发性高草酸尿症(PH)等单基因病因的早期发现,以便及时实施个体化诊疗。
要点
- 单基因结石病可通过遗传检测明确诊断,常染色体隐性原发性高草酸尿症(PH)为罕见类型。
- 3种类型PH均由肝脏乙醛酸代谢先天缺陷致肝性草酸盐生成过多和尿草酸盐排泄过多。
- 靶向肝脏的新型小干扰RNA疗法已获批,将精准医学引入1型原发性高草酸尿症治疗。
核心结论
- 作者认为,在生化评估之外更广泛地开展遗传检测可能确保更及时的诊断,使疑似单基因肾结石病患者获得更广泛的服务并进入临床试验和登记研究。
研究设计与样本
- 叙述性综述,作者汇总其操作流程、教育、培训和工作流程,以帮助其他临床医生将遗传评估整合到诊断常规中。
主要发现
- 作者经验表明,增加遗传检测的可及性有助于早期发现PH和其他单基因肾结石病病因,从而及时实施个体化诊疗。
- PH以肾结石、肾钙质沉着症、进行性慢性肾脏病和肾衰竭为特征。
- 当肾脏对草酸盐清除下降时,慢性肾脏病中可发生全身性草酸盐沉积症,导致严重疾病和死亡。
临床怎么用
- 作者认为,在生化评估之外更广泛地开展遗传检测可能确保更及时的诊断,使疑似单基因肾结石病患者获得更广泛的服务并进入临床试验和登记研究。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiple factors are thought to give rise to common, recurrent kidney stone disease, but for monogenic stone disorders a firm diagnosis is possible through genetic testing. The autosomal recessive primary hyperoxalurias (PH) are rare forms of monogenic kidney stone disease. All 3 types of PH are caused by inborn errors of glyoxylate metabolism in the liver, leading to hepatic oxalate overproduction and excessive renal urinary oxalate excretion. These conditions are characterized by kidney stones, nephrocalcinosis, progressive chronic kidney disease, and kidney failure. Systemic oxalosis, the extra-renal deposition of oxalate resulting in severe morbidity and mortality, occurs in chronic kidney disease when oxalate clearance by the kidneys declines. Novel small interfering RNA-based therapeutics targeting the liver to reduce urinary oxalate excretion have been approved, introducing precision medicine to treat primary hyperoxaluria type 1. The goal of this narrative review is to address the benefits and practicalities of genetic testing for suspected monogenic kidney stone disease and the critical roles of a multidisciplinary team. MATERIALS AND METHODS: We collated our procedures, education, training, and workflows to help other clinicians integrate genetic assessment into their diagnostic routines. RESULTS: In our experience, increased access to genetic testing facilitates early detection of PH and other monogenic causes of kidney stone disease so that individualized care can be instituted promptly. CONCLUSIONS: Alongside biochemical assessments, more widespread genetic testing may ensure more timely diagnoses so that patients with suspected monogenic kidney stone disease gain access to an expanded range of services and enrollment in clinical trials and registries.
引用
- Breeggemann MC, Harris PC, Lieske JC, et al. The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria. J Urol. 2024. PMID: 39093847. doi:10.1097/JU.0000000000004147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。